ClinicalTrials.gg
CompletedNCT04513912Updated Nov 13, 2026Results posted

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

A Phase 3 interventional study of Seltorexant and Matching placebo to Seltorexant in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 175 sites in 15 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
757
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.

Enrollment
Largest of 12
757 · median 176
Started
2020
with 3 others
Phase 3
5 of 12
2 open now
Registered
7th of 12
by date
Lead sponsor
11 of 12
Janssen Research & Development, LLC

Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one has the largest enrollment, is one of 4 that started in 2020, is one of 5 in phase 3, and was the 7th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About seltorexant

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing seltorexant in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Read the detailed description

Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet -5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (\<=) 24 months
  • Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (\<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
  • Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
  • Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
  • Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
  • (BMI) between 18 and 40 kilogram per meter square (kg/m\^2), inclusive (BMI=weight/height\^2)
  • Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead (ECG) performed at screening and baseline

Exclusion criteria

Exclusion Criteria:

  • Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency ( [CrCl] less than [\<] 30 milliliter per minute [mL/min]); or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
  • Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (\<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
  • Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
  • Has a history of moderate to severe substance use disorder including alcohol use disorder according to criteria within 6 months before screening
  • Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
757 participants (actual)

Study arms

  • Experimental
    Seltorexant

    Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.

    Drug: Seltorexant · Drug: Matching placebo to Seltorexant

  • Active comparator
    Quetiapine Extended-Release (XR)

    Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.

    Drug: Quetiapine XR · Drug: Matching placebo to Quetiapine XR

Interventions

  • Participants will receive seltorexant over-encapsulated tablet orally.

  • DrugMatching placebo to Seltorexant

    Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.

  • Participants will receive quetiapine XR capsule orally.

  • DrugMatching placebo to Quetiapine XR

    Participants will receive placebo capsule matching to quetiapine XR orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26

    Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with \>= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

    Time frame: Week 26

Secondary outcomes

  1. Change From Baseline to Week 26 in Weight

    Change from baseline to Week 26 in weight was reported.

    Time frame: Baseline (Day 1) and Week 26

  2. Time to Potentially Treatment Related Discontinuation of Study Drug

    Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used.

    Time frame: From first dose of study drug (Day 1) up to Week 30

  3. Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

    Time frame: Baseline (Day 1) and Week 26

  4. Change From Baseline to Week 26 in MADRS-6 Total Score

    Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition.

    Time frame: Baseline (Day 1) and Week 26

  5. Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score

    The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

    Time frame: Baseline (Day 1) and Week 26

  6. Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score

    Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement.

    Time frame: Baseline (Day 1) and Week 26

  7. Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26

    Percentage of participants with MADRS total score \<=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was \<=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

    Time frame: Week 26

  8. Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26

    Percentage of participants with a \>=50 percent improvement in MADRS total score and MADRS \<=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

    Time frame: Week 26

  9. Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26

    Percentage of participants with \>=7 percent weight increase from baseline at Week 26 was reported.

    Time frame: Week 26

07

Results

Posted Nov 13, 2026

Participant flow

Adult participants aged 18 to 64 years and elderly participants aged 65 to 74 years with major depressive disorder with insomnia symptoms (MDDIS), who had an inadequate response to ongoing antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) were randomized in the study.

DB Treatment Phase: Day 1 up to Week 26
Participant flow — DB Treatment Phase: Day 1 up to Week 26
MilestoneSeltorexantQuetiapine Extended-release (XR)
Started367390
Treated366390
Full analysis set 1 (fas1)355371
Completed277270
Not completed90120
Withdrew: Adverse event2144
Withdrew: Lack of efficacy54
Withdrew: Withdrawal by subject2746
Withdrew: Lost to follow-up97
Withdrew: Protocol violation33
Withdrew: Physician decision30
Withdrew: Non-compliance with study drug88
Withdrew: Non-compliance with primary antidepressant42
Withdrew: Initiated prohibited medication20
Withdrew: Other76
Withdrew: Randomized and not treated10
Follow-up Phase: Week 26 up to Week 28
Participant flow — Follow-up Phase: Week 26 up to Week 28
MilestoneSeltorexantQuetiapine Extended-release (XR)
Started328344
Completed299304
Not completed2940
Withdrew: Adverse event510
Withdrew: Withdrawal by subject1320
Withdrew: Lost to follow-up13
Withdrew: Other107

Outcome measures

PrimaryPercentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26

Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with \>= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
percentage of participantsSeltorexantQuetiapine Extended-release (XR)
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 2657.453.4
Statistical analysis
  • Seltorexant vs Quetiapine Extended-release (XR) · Cochran-Mantel-Haenszel · p = =0.2422 · Percentage difference: 4 · 95% CI -3.3 to 11.3
SecondaryChange From Baseline to Week 26 in Weight

Change from baseline to Week 26 in weight was reported.

Time frame:
Baseline (Day 1) and Week 26
Reported as:
Mean · Kilograms (Kg)
Change From Baseline to Week 26 in Weight
Kilograms (Kg)SeltorexantQuetiapine Extended-release (XR)
Change From Baseline to Week 26 in Weight0.5 ± 2.892.1 ± 3.93
Statistical analysis
  • Seltorexant vs Quetiapine Extended-release (XR) · Mixed model for repeated measures (MMRM) · p = <0.001 · Least square (ls) mean difference: -1.7 · 95% CI -2.23 to -1.09
SecondaryTime to Potentially Treatment Related Discontinuation of Study Drug

Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used.

Time frame:
From first dose of study drug (Day 1) up to Week 30
Reported as:
Median · days
Time to Potentially Treatment Related Discontinuation of Study Drug
daysSeltorexantQuetiapine Extended-release (XR)
Time to Potentially Treatment Related Discontinuation of Study DrugNA (NA to NA)206 (NA to NA)
SecondaryChange From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Time frame:
Baseline (Day 1) and Week 26
Reported as:
Mean · score on a scale
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scaleSeltorexantQuetiapine Extended-release (XR)
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-23.0 ± 10.12-22.7 ± 9.54
Statistical analysis
  • Seltorexant vs Quetiapine Extended-release (XR) · MMRM · p = =0.795 · Ls mean difference: -0.2 · 95% CI -1.77 to 1.35
SecondaryChange From Baseline to Week 26 in MADRS-6 Total Score

Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition.

Time frame:
Baseline (Day 1) and Week 26
Reported as:
Mean · score on a scale
Change From Baseline to Week 26 in MADRS-6 Total Score
score on a scaleSeltorexantQuetiapine Extended-release (XR)
Change From Baseline to Week 26 in MADRS-6 Total Score-14.8 ± 6.85-14.5 ± 6.64
SecondaryChange From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Time frame:
Baseline (Day 1) and Week 26
Reported as:
Mean · score on a scale
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
score on a scaleSeltorexantQuetiapine Extended-release (XR)
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score-19.9 ± 9.22-19.5 ± 8.64
Statistical analysis
  • Seltorexant vs Quetiapine Extended-release (XR) · MMRM · p = =0.623 · Ls mean difference: -0.4 · 95% CI -1.77 to 1.06
SecondaryChange From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score

Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement.

Time frame:
Baseline (Day 1) and Week 26
Reported as:
Mean · score on a scale
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
score on a scaleSeltorexantQuetiapine Extended-release (XR)
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score-12.1 ± 6.36-12.5 ± 5.95
Statistical analysis
  • Seltorexant vs Quetiapine Extended-release (XR) · Ls mean difference: 0.2 · 95% CI -0.70 to 1.19
SecondaryPercentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26

Percentage of participants with MADRS total score \<=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was \<=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
percentage of participantsSeltorexantQuetiapine Extended-release (XR)
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 2646.943.5
SecondaryPercentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26

Percentage of participants with a \>=50 percent improvement in MADRS total score and MADRS \<=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
percentage of participantsSeltorexantQuetiapine Extended-release (XR)
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 2657.152.1
SecondaryPercentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26

Percentage of participants with \>=7 percent weight increase from baseline at Week 26 was reported.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
percentage of participantsSeltorexantQuetiapine Extended-release (XR)
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 264.418.3

Adverse events

Collected over DB Phase: From Day 1 up to Week 30, Follow-up Phase: From Week 30 up to Week 32. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind Phase: Seltorexant0/366 (0%)5/366 (1.4%)99/366 (27%)
Double Blind Phase: Quetiapine XR0/390 (0%)6/390 (1.5%)200/390 (51.3%)
Follow-up Phase : Seltorexant0/328 (0%)2/328 (0.6%)5/328 (1.5%)
Follow-up Phase: Quetiapine XR0/344 (0%)0/344 (0%)8/344 (2.3%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventDouble Blind Phase: SeltorexantDouble Blind Phase: Quetiapine XRFollow-up Phase : SeltorexantFollow-up Phase: Quetiapine XR
Panic AttackPsychiatric disorders0/3660/3901/3280/344
Suicide AttemptPsychiatric disorders0/3660/3901/3280/344
Drug-Induced Liver InjuryHepatobiliary disorders1/3660/3900/3280/344
Covid-19Infections and infestations1/3660/3900/3280/344
OsteonecrosisMusculoskeletal and connective tissue disorders1/3660/3900/3280/344
DepressionPsychiatric disorders1/3660/3900/3280/344
Cervical DysplasiaReproductive system and breast disorders1/3660/3900/3280/344
AnaemiaBlood and lymphatic system disorders0/3661/3900/3280/344
PalpitationsCardiac disorders0/3661/3900/3280/344
Haemorrhoidal HaemorrhageGastrointestinal disorders0/3661/3900/3280/344
Most frequent other events
Most frequent other events
EventDouble Blind Phase: SeltorexantDouble Blind Phase: Quetiapine XRFollow-up Phase : SeltorexantFollow-up Phase: Quetiapine XR
SomnolenceNervous system disorders23/36694/3900/3280/344
Weight IncreasedInvestigations20/36654/3901/3282/344
HeadacheNervous system disorders42/36643/3903/3285/344
Dry MouthGastrointestinal disorders10/36638/3900/3280/344
FatigueGeneral disorders13/36623/3900/3282/344
NauseaGastrointestinal disorders11/36620/3901/3280/344

Baseline characteristics

Baseline characteristics are reported for FAS2 analysis set which included all randomized participants who received at least 1 dose of study intervention.

Age, Categorical
Age, Categorical(Participants)SeltorexantQuetiapine Extended-release (XR)Total
<=18 years000
Between 18 and 65 years337349686
>=65 years294170
Age, Continuous
Age, Continuous(years)SeltorexantQuetiapine Extended-release (XR)Total
Mean47.8 ± 13.1547.9 ± 13.6447.9 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)SeltorexantQuetiapine Extended-release (XR)Total
Female281277558
Male85113198
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SeltorexantQuetiapine Extended-release (XR)Total
Hispanic or Latino7983162
Not Hispanic or Latino284301585
Unknown or Not Reported369
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SeltorexantQuetiapine Extended-release (XR)Total
American Indian or Alaska Native101
Asian131326
Native Hawaiian or Other Pacific Islander112
Black or African American172138
White327351678
More than one race628
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(Participants)SeltorexantQuetiapine Extended-release (XR)Total
Argentina424688
Belgium123
Bulgaria484795
Canada011
Czech Republic171633
Latvia81018
Lithuania6915
Malaysia101222
Poland151732
Russian Federation151833
Serbia5457111
Slovakia292857
Ukraine101323
United Kingdom112
United States110113223
08

Study locations

175 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • SW Biomedical Research LLC
    Tucson, Arizona 85712, United States
  • Proscience Research Group
    Culver City, California 90230, United States
  • Pharmacology Research Institute
    Encino, California 91316, United States
  • Collaborative NeuroScience Network
    Garden Grove, California 92845, United States
  • Collaborative NeuroScience Network
    Long Beach, California 90806, United States
  • Pharmacology Research Institute
    Los Alamitos, California 90720, United States
  • CalNeuro Research
    Los Angeles, California 90025, United States
  • Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Pacific Neuropsychiatric Specialists
    Orange, California 92868, United States
  • CNRI-Los Angeles, LLC
    Pico Rivera, California 90660, United States
  • Prospective Research Innovations Inc
    Rancho Cucamonga, California 91730, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • University of California at San Diego
    San Diego, California 92103, United States
  • National Research Institute
    Santa Ana, California 91704, United States
  • CI Trials
    Santa Ana, California 92705, United States
  • CMB Clinical Trials
    Santee, California 92071, United States
  • Schuster Medical Research Institute
    Sherman Oaks, California 91403, United States
  • Pacific Clinical Research Medical Group
    Upland, California 91786, United States
  • Hartford Hospital
    Hartford, Connecticut 06102, United States
  • Moonshine Research Center, Inc
    Doral, Florida 33166, United States
  • Velocity Clinical Research, Hallandale Beach
    Hallandale, Florida 33009, United States
  • Indago Research & Health Center Inc
    Hialeah, Florida 33012, United States
  • New Life Medical Research Center, Inc.
    Hialeah, Florida 33012, United States
  • Amedica Research Institute Inc
    Hialeah, Florida 33013, United States
  • Meridien Research
    Lakeland, Florida 33803, United States
  • Premier Clinical Research
    Miami, Florida 33122, United States
  • Global Medical Institutes
    Miami, Florida 33125, United States
  • Miami Jewish Health System
    Miami, Florida 33137, United States
  • Clinical Neuroscience Solutions
    Orlando, Florida 23801, United States
  • Synexus Research Orlando
    Orlando, Florida 32806, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Compass Research LLC-Bioclinica Research
    The Villages, Florida 32162, United States
  • Synexus Clinical Research US Inc
    Atlanta, Georgia 30328, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • iResearch Atlanta LLC
    Decatur, Georgia 30030, United States
  • Psych Atlanta, P.C.
    Marietta, Georgia 30060, United States
  • Chicago Research Center
    Chicago, Illinois 60634, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • Alexian Brothers Health System
    Lisle, Illinois 60532, United States
  • Baber Research Group
    Naperville, Illinois 60563, United States
  • Lemah Creek Clinical Research
    Oakbrook Terrace, Illinois 60618, United States
  • Ascension via Christi Research
    Wichita, Kansas 67214, United States
  • Riverstar Research
    New Orleans, Louisiana 70115, United States
  • Pharmasite Research, Inc.
    Baltimore, Maryland 21208, United States
  • BTC of New Bedford
    New Bedford, Massachusetts 02740, United States
  • Boston Clinical Trials & Medical Research
    Roslindale, Massachusetts 02135, United States
  • Psychiatric Care and Research Center (PCRC)
    O'Fallon, Missouri 63368, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • SPRI Clinical Trials, LLC
    Brooklyn, New York 11235, United States
  • Fieve Clinical Research Inc
    New York, New York 10017, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618 1609, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Velocity Clinical Research, Inc.
    Durham, North Carolina 27701, United States
  • University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
    Cincinnati, Ohio 45219, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Neuro Behavioral Clinical Research
    North Canton, Ohio 44720, United States
  • Sooner Clinical Research
    Oklahoma City, Oklahoma 73112, United States
  • Paradigm Research Professionals, LLC
    Oklahoma City, Oklahoma 73118, United States
  • Suburban Research Associates
    Pine Hill, Pennsylvania 08021, United States
  • Global Medical Institutes
    Scranton, Pennsylvania 18503, United States
  • Coastal Carolina Research Center
    Mt. Pleasant, South Carolina 29464, United States
  • West Houston Clinical Research Service
    Bellaire, Texas 77401, United States
  • North Texas Clinical Trials
    Fort Worth, Texas 76104, United States
  • Hawkins Psychiatry, PC
    Mansfield, Texas 76054, United States
  • Family Psychiatry of The Woodlands
    The Woodlands, Texas 77381, United States
  • Grayline Research Center
    Wichita Falls, Texas 76309, United States
  • Alpine Research Organization
    Clinton, Utah 84015, United States
  • Cedar Clinical Research
    Draper, Utah 84020, United States
  • University of Virginia
    Charlottesville, Virginia 22903, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
  • Cary J. Kohlenberg, MD, SC, dba, IPC Research.
    Waukesha, Wisconsin 53188, United States
  • CENydET - Centro Neurobiologico y de Stress Traumatico
    Buenos Aires, 1058AAJ, Argentina
  • Hospital Italiano
    Buenos Aires, 1199, Argentina
  • FunDaMos
    Buenos Aires, C1405BOA, Argentina
  • Hospital Fleni
    Ciudad Autonoma Buenos Aires, C1428AQK, Argentina
  • Fundacion Lennox
    Córdoba, 5000, Argentina
  • Instituto Privado Kremer
    Córdoba, X5004AOA, Argentina
  • Centro Medico Luquez
    Córdoba, X5006IKK, Argentina
  • CENPIA
    La Plata, 1902, Argentina
  • Clinica Privada de Salud Mental Santa Teresa de Ávila
    La Plata, Thanks, Argentina
  • CENAIN
    Mendoza, M5502AWY, Argentina
  • Clinica Mayo de UMCB
    San Miguel de Tucumán, 4000, Argentina
  • AZ Sint-Lucas
    Bruges, 8310, Belgium
  • AZ Nikolaas
    Sint-Niklaas, 9100, Belgium
  • Medical Center Medconsult-Pleven
    Pleven, 5800, Bulgaria
  • MC 'Hipokrat - N', EOOD
    Plovdiv, 4028, Bulgaria
  • Mental Health Center - Rousse
    Rousse, 7003, Bulgaria
  • Medical Center St. Naum
    Sofia, 1113, Bulgaria
  • Medical Center Intermedica, OOD
    Sofia, 1680, Bulgaria
  • MC 'Synexus Sofia' EOOD
    Sofia, 1784, Bulgaria
  • MC 'Synexus Sofia' EOOD
    Stara Zagora, 6000, Bulgaria
  • UMHAT Prof. Dr. St. Kirkovich AD
    Stara Zagora, 6003, Bulgaria
  • State Psychiatric Hospital - Tzarev Brod
    Tzarev Brod, 9747, Bulgaria
  • Diagnostic Consulting Center Mladost - M Varna
    Varna, 9020, Bulgaria
  • Mental Health Center - Veliko Tarnovo EOOD
    Veliko Tarnovo, 5000, Bulgaria
  • A.K. Munshi Medical Inc.
    Sydney, Nova Scotia B1P 1E1, Canada

Showing the first 100 of 175 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Oct 2023, 36 months.

Results were first posted in Nov 2026, 3 years 1 month after primary completion. A results delay was requested in Oct 2024.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 36 months is above that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2020
First posted
Aug 14, 2020
StartActual
Sep 15, 2020
Primary completionActual
Oct 3, 2023
CompletionActual
Oct 3, 2023
Results delay requested
Oct 2, 2024
Results first posted
Nov 13, 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Zaporizhzhia Regional Clinical Hospital · Zaporizhzhya, Ukraine
Show 1 removed
  • Zaporizhzhia Regional Clinical Hospital · Zaporizhzhia, Ukraine
Nov 13, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedPercentage of Participants withWho Achieved Response (Greater Than or Equal to [>=50] Percent improvementImprovement in Montgomery-Asberg Depression Rating Scale [MADRS total score from baseline] Total Score From Baseline) at Week 26Time frame: Week 26
Nov 13, 2026
Documents
Secondary outcomes
9 edited
What changed in the outcomes
  • EditedChange from baseline in Weight upFrom Baseline to Week 26 in WeightTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
  • EditedTime to Study Drug Discontinuation for Potentially Treatment Related ReasonsDiscontinuation of Study DrugTime frame: Up to Week 26 → From first dose of study drug (Day 1) up to Week 30
  • EditedChange fromFrom Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
  • EditedChange fromFrom Baseline to Week 26 in MADRS-6 Total ScoreTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
  • EditedChange fromFrom Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total ScoreTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
  • EditedChange fromFrom Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total ScoreTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
  • EditedPercentage of Participants with Remission (With MADRS Total Score less thanLess Than or equalEqual to (<=) 12) at Week 26Time frame: Week 26
  • EditedPercentage of Participants withWith a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26Time frame: Week 26
  • EditedPercentage of Participants with Weight IncreaseWith >=7 Percent fromWeight Increase From Baseline at Week 26Time frame: Week 26
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Results posted
    1 site added, 1 site removed
    Show site
    • Zaporizhzhia Regional Clinical Hospital · Zaporizhzhya, Ukraine
    Show 1 removed
    • Zaporizhzhia Regional Clinical Hospital · Zaporizhzhia, Ukraine
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentage of Participants withWho Achieved Response (Greater Than or Equal to [>=50] Percent improvementImprovement in Montgomery-Asberg Depression Rating Scale [MADRS total score from baseline] Total Score From Baseline) at Week 26Time frame: Week 26
    Secondary outcomes 9 edited
    What changed in the outcomes
    • EditedChange from baseline in Weight upFrom Baseline to Week 26 in WeightTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
    • EditedTime to Study Drug Discontinuation for Potentially Treatment Related ReasonsDiscontinuation of Study DrugTime frame: Up to Week 26 → From first dose of study drug (Day 1) up to Week 30
    • EditedChange fromFrom Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
    • EditedChange fromFrom Baseline to Week 26 in MADRS-6 Total ScoreTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
    • EditedChange fromFrom Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total ScoreTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
    • EditedChange fromFrom Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total ScoreTime frame: Baseline to Week 26 → Baseline (Day 1) and Week 26
    • EditedPercentage of Participants with Remission (With MADRS Total Score less thanLess Than or equalEqual to (<=) 12) at Week 26Time frame: Week 26
    • EditedPercentage of Participants withWith a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26Time frame: Week 26
    • EditedPercentage of Participants with Weight IncreaseWith >=7 Percent fromWeight Increase From Baseline at Week 26Time frame: Week 26
    + 3 other changes: verification date, registry dates and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04513912
Responsible party
Sponsor
First posted
Aug 14, 2020
Start date
Sep 15, 2020
Primary completion
Oct 3, 2023
Completion
Oct 3, 2023
Results posted
Nov 13, 2026
Last update
Nov 13, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seltorexant

Start the discussion